Viridian Therapeutics Enters Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug

On May 24, 2026, Viridian Therapeutics entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited. Under the terms of the agreement, WuXi Biologics will serve as a non-exclusive manufacturer and supplier for the drug substance and drug product of veligrotug, Viridian's candidate for thyroid eye disease, to meet anticipated long-term commercial requirements upon potential regulatory approval. The agreement establishes volume-based pricing, with service fees fixed through December 31, 2026, followed by annual adjustments. Viridian is required to provide monthly rolling forecasts, a portion of which will constitute binding commitments. The contract has an initial five-year term with automatic five-year renewals, subject to a 24-month non-renewal notice period. This partnership secures a critical component of Viridian's supply chain as it prepares for the potential commercial launch of veligrotug.